These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 31434793)

  • 1. Bicalutamide plus Aromatase Inhibitor in Patients with Estrogen Receptor-Positive/Androgen Receptor-Positive Advanced Breast Cancer.
    Lu Q; Xia W; Lee K; Zhang J; Yuan H; Yuan Z; Shi Y; Wang S; Xu F
    Oncologist; 2020 Jan; 25(1):21-e15. PubMed ID: 31434793
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer.
    Gucalp A; Tolaney S; Isakoff SJ; Ingle JN; Liu MC; Carey LA; Blackwell K; Rugo H; Nabell L; Forero A; Stearns V; Doane AS; Danso M; Moynahan ME; Momen LF; Gonzalez JM; Akhtar A; Giri DD; Patil S; Feigin KN; Hudis CA; Traina TA;
    Clin Cancer Res; 2013 Oct; 19(19):5505-12. PubMed ID: 23965901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The potential clinical benefit of targeting androgen receptor (AR) in estrogen-receptor positive breast cancer cells treated with Exemestane.
    Amaral C; Augusto TV; Almada M; Cunha SC; Correia-da-Silva G; Teixeira N
    Biochim Biophys Acta Mol Basis Dis; 2020 May; 1866(5):165661. PubMed ID: 31891807
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Androgen Receptor Expression and Bicalutamide Antagonize Androgen Receptor Inhibit β-Catenin Transcription Complex in Estrogen Receptor-Negative Breast Cancer.
    Huang R; Han J; Liang X; Sun S; Jiang Y; Xia B; Niu M; Li D; Zhang J; Wang S; Wei W; Liu Q; Zheng W; Zhang G; Song Y; Panga D
    Cell Physiol Biochem; 2017; 43(6):2212-2225. PubMed ID: 29069648
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serial [
    Boers J; Venema CM; de Vries EFJ; Hospers GAP; Boersma HH; Rikhof B; Dorbritz C; Glaudemans AWJM; Schröder CP
    Eur J Cancer; 2021 Feb; 144():151-161. PubMed ID: 33341447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Niclosamide and Bicalutamide Combination Treatment Overcomes Enzalutamide- and Bicalutamide-Resistant Prostate Cancer.
    Liu C; Armstrong CM; Lou W; Lombard AP; Cucchiara V; Gu X; Yang JC; Nadiminty N; Pan CX; Evans CP; Gao AC
    Mol Cancer Ther; 2017 Aug; 16(8):1521-1530. PubMed ID: 28500234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Carbidopa enhances antitumoral activity of bicalutamide on the androgen receptor-axis in castration-resistant prostate tumors.
    Thomas C; Wafa LA; Lamoureux F; Cheng H; Fazli L; Gleave ME; Rennie PS
    Prostate; 2012 Jun; 72(8):875-85. PubMed ID: 22072572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II Study of Dehydroepiandrosterone in Androgen Receptor-Positive Metastatic Breast Cancer.
    Pietri E; Massa I; Bravaccini S; Ravaioli S; Tumedei MM; Petracci E; Donati C; Schirone A; Piacentini F; Gianni L; Nicolini M; Campadelli E; Gennari A; Saba A; Campi B; Valmorri L; Andreis D; Fabbri F; Amadori D; Rocca A
    Oncologist; 2019 Jun; 24(6):743-e205. PubMed ID: 30591548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II trial of RAD001 and bicalutamide for castration-resistant prostate cancer.
    Nakabayashi M; Werner L; Courtney KD; Buckle G; Oh WK; Bubley GJ; Hayes JH; Weckstein D; Elfiky A; Sims DM; Kantoff PW; Taplin ME
    BJU Int; 2012 Dec; 110(11):1729-35. PubMed ID: 22928480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study.
    Shore ND; Chowdhury S; Villers A; Klotz L; Siemens DR; Phung D; van Os S; Hasabou N; Wang F; Bhattacharya S; Heidenreich A
    Lancet Oncol; 2016 Feb; 17(2):153-163. PubMed ID: 26774508
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: Updated Results of ALTERNATIVE.
    Johnston SRD; Hegg R; Im SA; Park IH; Burdaeva O; Kurteva G; Press MF; Tjulandin S; Iwata H; Simon SD; Kenny S; Sarp S; Izquierdo MA; Williams LS; Gradishar WJ
    J Clin Oncol; 2021 Jan; 39(1):79-89. PubMed ID: 32822287
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exemestane versus anastrozole as front-line endocrine therapy in postmenopausal patients with hormone receptor-positive, advanced breast cancer: final results from the Spanish Breast Cancer Group 2001-03 phase 2 randomized trial.
    Llombart-Cussac A; Ruiz A; Antón A; Barnadas A; Antolín S; Alés-Martínez JE; Alvarez I; Andrés R; García Saenz JA; Lao J; Carrasco E; Cámara C; Casas I; Martín M
    Cancer; 2012 Jan; 118(1):241-7. PubMed ID: 21717449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized phase II trial on the addition of dutasteride to combined androgen blockade therapy versus combined androgen blockade therapy alone in patients with advanced or metastatic salivary duct carcinoma - the DUCT study protocol.
    Weijers JAM; Verhaegh GW; Lassche G; van Engen-van Grunsven ACH; Driessen CML; van Erp NP; Jonker MA; Schalken JA; van Herpen CML
    BMC Cancer; 2024 Sep; 24(1):1174. PubMed ID: 39304797
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide.
    Cochrane DR; Bernales S; Jacobsen BM; Cittelly DM; Howe EN; D'Amato NC; Spoelstra NS; Edgerton SM; Jean A; Guerrero J; Gómez F; Medicherla S; Alfaro IE; McCullagh E; Jedlicka P; Torkko KC; Thor AD; Elias AD; Protter AA; Richer JK
    Breast Cancer Res; 2014 Jan; 16(1):R7. PubMed ID: 24451109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of bicalutamide sensitivity in prostate cancer cells by an epigenetic Puralpha-mediated decrease in androgen receptor levels.
    Liu X; Gomez-Pinillos A; Liu X; Johnson EM; Ferrari AC
    Prostate; 2010 Feb; 70(2):179-89. PubMed ID: 19790234
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Bicalutamide on the proliferation and invasion of human triple negative breast cancer MDA-MB-231 cells.
    Kong Y; Qu F; Yuan X; Yan X; Yu W
    Medicine (Baltimore); 2020 Apr; 99(17):e19822. PubMed ID: 32332626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spotlight on bicalutamide 150mg in the treatment of locally advanced prostate cancer.
    Wellington K; Keam SJ
    Drugs Aging; 2007; 24(2):169-71. PubMed ID: 17313204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overcoming aromatase inhibitor resistance in breast cancer: possible mechanisms and clinical applications.
    Hanamura T; Hayashi SI
    Breast Cancer; 2018 Jul; 25(4):379-391. PubMed ID: 28389808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First-line endocrine therapy for postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer: a systematic review and meta-analysis.
    Shimoi T; Sagara Y; Hara F; Toyama T; Iwata H
    Breast Cancer; 2020 May; 27(3):340-346. PubMed ID: 32043218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II study of combined fulvestrant and everolimus in patients with metastatic estrogen receptor (ER)-positive breast cancer after aromatase inhibitor (AI) failure.
    Massarweh S; Romond E; Black EP; Van Meter E; Shelton B; Kadamyan-Melkumian V; Stevens M; Elledge R
    Breast Cancer Res Treat; 2014 Jan; 143(2):325-32. PubMed ID: 24327334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.